WW price target lowered to $3 from $9 at UBS

UBS analyst Michael Lasser lowered the firm’s price target on WW to $3 from $9 and keeps a Neutral rating on the shares. While WW’s core member base is increasing modestly with the hopes of converting to Clinical, sentiment was negatively impacted by the announcement that Director Oprah Winfrey decided not to stand for re-election at the company’s upcoming annual meeting of shareholders to be held in May, the analyst tells investors in a research note. The firm thinks the risk/reward remains balanced.